RiskMastery's Breakout Stocks - CYP EditionWelcome to RiskMastery's Breakout Stocks - Stocks with breakout potential.
In this edition, we'll be looking at ASX:CYP ...
I believe this code is at a point of potential volatility.
If price can hold above $0.200 ... Bullish potential may be unlocked.
My key upside targets include:
-
−0.090AUD
−14.28 MAUD
154.32 M
About CYNATA THERAPEUTICS LIMITED
Sector
Industry
CEO
Kilian Kelly
Website
Headquarters
Cremorne
Founded
2003
ISIN
AU000000CYP7
FIGI
BBG000TKBTN2
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.
Broken trend now looking for run higherDowntrend was broken at the start of the month with good volume but yet to really offer big breakout. Looking for a fill up to 0.775 (resistance from early jan). Once past that, not much stopping it up to 0.870 or higher.
Stop at 0.655 which looks like a base
RSI has plenty of room run
CYP - Technical Bullish Flag + CV TailwindsClassic bullish flag forming in the Cynata Therapeutics chart. Not the best time for the technicals to line up as far as the overall market in concerned, but this looks to be High probabilty trade on the back of their cv19 tailwinds/fundamentals as they turn their attention to virus treatments (cv19
$CYP - CYNATA - Up or Down ?Cynata has been having a good run of late, but is back up against its previous all time high. If it can push through I would take a punt on it to continue. It hit $1.65 in todays early trade but back down to $1.52 now. One to watch for now.
Cynata Therapeutics Limited is a stem cell and regenerativ
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CYP is 0.210 AUD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange CYNATA THERAPEUTICS LIMITED stocks are traded under the ticker CYP.
CYNATA THERAPEUTICS LIMITED is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
CYP stock is 4.88% volatile and has beta coefficient of 0.37. Check out the list of the most volatile stocks — is CYNATA THERAPEUTICS LIMITED there?
CYP earnings for the last quarter are −0.02 AUD per share, whereas the estimation was −0.04 AUD resulting in a 37.75% surprise. The estimated earnings for the next quarter are −0.04 AUD per share. See more details about CYNATA THERAPEUTICS LIMITED earnings.
Yes, you can track CYNATA THERAPEUTICS LIMITED financials in yearly and quarterly reports right on TradingView.
CYP stock has risen by 13.51% compared to the previous week, the month change is a 16.67% rise, over the last year there was no change in CYNATA THERAPEUTICS LIMITED price.
CYP net income for the last quarter is −4.54 M AUD, while the quarter before that showed −9.10 M AUD of net income which accounts for 50.12% change. Track more CYNATA THERAPEUTICS LIMITED financial stats to get the full picture.
Today CYNATA THERAPEUTICS LIMITED has the market capitalization of 37.72 M, it has decreased by 2.70% over the last week.
No, CYP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYNATA THERAPEUTICS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CYNATA THERAPEUTICS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CYNATA THERAPEUTICS LIMITED stock shows the neutral signal. See more of CYNATA THERAPEUTICS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.